Although we did not assess the neutralizing ability of the identified autoantibodies against IFN-ω, IFN-α-2a and IL-22, the results obtained allowed us to correctly identify 18/18 patients with APS-1. This evidence concerns the gene IFNA2 and autoimmune polyendocrine syndrome type 1.